CN103127098B - Anti-cancer pharmaceutical composition containing clavulanic acid or salts thereof and pharmaceutical application - Google Patents
Anti-cancer pharmaceutical composition containing clavulanic acid or salts thereof and pharmaceutical application Download PDFInfo
- Publication number
- CN103127098B CN103127098B CN201310094091.5A CN201310094091A CN103127098B CN 103127098 B CN103127098 B CN 103127098B CN 201310094091 A CN201310094091 A CN 201310094091A CN 103127098 B CN103127098 B CN 103127098B
- Authority
- CN
- China
- Prior art keywords
- clavulanic acid
- salt
- pharmaceutical composition
- oxaliplatin
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 title claims abstract description 50
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 229960003324 clavulanic acid Drugs 0.000 title claims abstract description 45
- 150000003839 salts Chemical class 0.000 title claims abstract description 32
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 27
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 16
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims description 10
- 229940038649 clavulanate potassium Drugs 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 208000000649 small cell carcinoma Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an anti-cancer pharmaceutical composition containing clavulanic acid or salts thereof and an application. The active ingredients of the composition consist of clavulanic acid or salts thereof and oxaliplatin. The anti-cancer medicine composition provided by the invention enriches the prior art, a new potential anti-cancer medicine is developed for clinic, and the anti-cancer pharmaceutical composition has obvious social meaning and economic meaning.
Description
Technical field
The invention belongs to medical technical field, in particular to a kind of cancer therapy drug, relate in particular to a kind of anticancer pharmaceutical composition that contains clavulanic acid or its salt and pharmaceutical applications.
Background technology
Cancer is common frdquently encountered disease, and the people's life and healthy in serious harm, due to the position difference of pathogenesis of cancer, can have various cancer, as nonsmall-cell lung cancer, gastric cancer, pulmonary carcinoma, osteocarcinoma, skin carcinoma, intestinal cancer, hepatocarcinoma etc.Nonsmall-cell lung cancer (Non-small-cell carcinoma) and " non-small cell carcinoma " synonym.Non-small cell type pulmonary carcinoma, comprises scale cancer, adenocarcinoma, large cell carcinoma, compared with small cell carcinoma the division of its growth of cancer cells slower, diffusion transfer is evening relatively.Nonsmall-cell lung cancer accounts for the 80-85% of the total placate of pulmonary carcinoma.
The treatment of nonsmall-cell lung cancer will be carried out according to the clinical stages of pulmonary carcinoma.To I, II, III A phase, mainly take excision as main, lymph metastasis shows author, before operation, can be aided with chemotherapy or radiotherapy.In the past few decades postoperative patients with lung cancer is all carried out to conventional chemotherapy, find now that postoperative I phase chemotherapy person's life cycle and the postoperative chemotherapy person's of not having life cycle are the same, that is to say that postoperative I phase chemotherapy is invalid.Past, postoperation radiotherapy formed a kind of conventional to II phase and III a phase patient, research discovery now, and this can obviously shorten the survival of patients phase, is harmful to.After underwent operative, 5 years survival rates approximately 70% of I phase patient, 5 years II phases survival rate approximately 50%, the III phase 5 years survival rate 15-30% of chemoradiotherapy therapeutic alliance person that maybe can not perform the operation that can perform an operation, radiation alone is 5-10%.Cannot operative treatment to (having invaded contiguous important organ) IV phase III B phase (existing metastasis) patient, this type of sufferer can consider to accept chemicals, radiation cure or traditional Chinese medical herbal treatment, but nonsmall-cell lung cancer is poor to the sensitivity of radiotherapy, finding effective Therapeutic Method is the problem that current Treatment for Non-small Cell Lung is needed solution badly." clinical observation of docetaxel injection combined with oxaliplatin in advanced non-small cell lung cancer " (modern tumor medical science, 2010 01 month, the 18th volume the 01st phase 100-101 page) Docetaxel administration associating oxaliplatin first-line treatment advanced Non-small cell lung determined curative effect weekly disclosed, untoward reaction is lighter, better tolerance is a kind of safe and effective, method that clinic is applied.
Clavulanic acid claims again clavulanic acid, for streptomycete produce new for oxygen parent nucleus beta-Lactam antibiotic, belong to irreversibility competitive type beta-lactamase inhibitor, with after enzyme strong bonded, make enzyme deactivation, thereby effect is strong, not only act on the β of golden Portugal bacterium--lactamase, again the beta-lactamase of gram negative bacilli is also had to effect.Share and greatly improved antibacterial activity with penicillins or cephalosporins, can make its minimum inhibitory concentration (MIC) obviously decline, medicine can potentiation several times to tens times, makes Resistant strain recover its sensitivity.The product about clavulanic acid having gone on the market is all compound products that itself and other antibiotic is made, such as amoxicillin/clavulanate potassium, ticarcillin and clavulanate potassium etc., for urethra and respiratory tract infection due to escherichia coli, various Bacillus proteus, scorching bacillus, hemophilus influenza, streptococcus pneumoniae etc.
At present, also do not have bibliographical information clavulanic acid to can be used to anti-nonsmall-cell lung cancer, there is no bibliographical information by clavulanic acid and oxaliplatin application for the treatment of nonsmall-cell lung cancer yet.
Summary of the invention
The inventor is surprised to find that when respiratory system infection under application amoxicillin and clavulanate potassium treatment, and clavulanate potassium coordinates oxaliplatin to have comparatively significant tumor-inhibiting action to Patients with Non-small-cell Lung.Confirm that by internal and external test heavy dose of clavulanate potassium has certain antitumor activity really subsequently, also confirmed that clavulanate potassium associating oxaliplatin has more significant Synergistic anti-cancer effect simultaneously.Therefore, the object of the present invention is to provide a kind of anticancer pharmaceutical composition that contains clavulanic acid or its salt and pharmaceutical applications.
The inventor studies by lot of experiments, has finally obtained following technical scheme:
An anticancer pharmaceutical composition that contains clavulanic acid or its salt, active component is made up of clavulanic acid or its salt and oxaliplatin.
Term " salt of clavulanic acid " is herein the addition salts of clavulanic acid.Because clavulanic acid is unstable, be prepared into addition salts rear stability and improve, be conducive to production and the preservation of preparation, therefore clavulanic acid is applied in pharmaceutical preparation with the form of salt conventionally.In addition, it should be noted that, the salt of clavulanic acid can be metabolized to active component clavulanic acid in vivo, then brings into play pharmaceutically active.
Preferably, above-mentioned anticancer pharmaceutical composition, the salt of clavulanic acid is by free acid, and the weight ratio of clavulanic acid or its salt and oxaliplatin is 1:0.1-2.
Further preferably, above-mentioned anticancer pharmaceutical composition, the salt of clavulanic acid is by free acid, and the weight ratio of clavulanic acid or its salt and oxaliplatin is 1:0.2-0.5.
Above-mentioned anticancer pharmaceutical composition, the salt of clavulanic acid is preferably clavulanate potassium.
Above-mentioned anticancer pharmaceutical composition is preferably injection, and described injection is injection, freeze-dried powder, non-freeze-dried powder.
Term " non-freeze-dried powder " herein refers to that clavulanic acid or its salt and oxaliplatin material powder mix mixed powder under gnotobasis, this mixed powder add or do not add adjuvant after directly pack in cillin bottle and be prepared from.The subpackage ambient humidity of preferred non-freeze-dried powder is controlled at below 30%.
Again further preferably, above-mentioned anticancer pharmaceutical composition, the salt of clavulanic acid is by free acid, and the effective dose that in described preparation, per unit preparation contains clavulanic acid or its salt is 100mg-400mg, and the effective dose that contains oxaliplatin is 50mg-100mg.
Test confirms: heavy dose of clavulanic acid has certain active anticancer, can significantly suppress the growth of people's lung cancer A549 cell transplanted tumor in nude mice.Therefore, second object of the present invention is to provide a kind of pharmaceutical applications of compound, i.e. clavulanic acid or its salt purposes in the medicine of the anti-nonsmall-cell lung cancer of preparation.In addition, in test, also find, compared with oxaliplatin group or clavulanic acid group, the average tumour inhibiting rate of drug combination group is significantly increased, the tumour inhibiting rate that especially connection is compared each single medicine group with medication B group have highly significant difference (
p< 0.01), this illustrates that heavy dose of clavulanic acid associating oxaliplatin has the effect of collaborative anti-nonsmall-cell lung cancer.Therefore, the 3rd object of the present invention is to provide a kind of pharmaceutical applications of compound, the purposes of the active component being made up of clavulanic acid or its salt and oxaliplatin in the medicine of the anti-nonsmall-cell lung cancer of preparation.
The anticancer pharmaceutical composition that contains clavulanic acid or its salt provided by the invention has enriched prior art, for having increased clinically a kind of potential PTS, has social meaning and the economic implications of highly significant.
The specific embodiment
Further illustrate the present invention below by embodiment.Embodiments of the invention are only used for illustrating the present invention, rather than limitation of the present invention, under design prerequisite of the present invention, the simple modifications of preparation method of the present invention are all belonged to the scope of protection of present invention.
Embodiment clavulanate potassium and clavulanate potassium and the oxaliplatin coupling impact on the growth of people's lung cancer A549 cell transplanted tumor in nude mice:
60 of SPF level BALB/c-nu mices, 6 week age, body weight l6g-18 g.The trophophase lung cancer cell line A549 cell of taking the logarithm, adjusting A549 cell concentration with aseptic PBS is 3 × 10
7/ mL, at BALB/c-nu mouse back subcutaneous vaccination A549 cell 0.1ml, treats that subcutaneous transplantation tumor volume reaches 75 mm
3(about l0d) when the left and right, model manufacturing success.
Be divided into following five groups by tumor volume and mice with tumor body weight homeostatic principle, 12 every group:
Model control group: intraperitoneal injection of saline, the next day administration 1 time, amount to 8 times;
Oxaliplatin group: lumbar injection 10mg/kg/d oxaliplatin, the next day administration 1 time, amount to 8 times.
Clavulanic acid group: lumbar injection 20mg/kg/d clavulanic acid, the next day administration 1 time, amount to 8 times.
Connection and medication A group: lumbar injection 10mg/kg/d clavulanic acid+5mg/kg/d oxaliplatin, the next day administration 1 time, 8 times altogether.
Connection and medication B group: lumbar injection 15mg/kg/d clavulanic acid+5mg/kg/d oxaliplatin, the next day administration 1 time, 8 times altogether.
During administration every 4 days with the major diameter (L) of vernier caliper measurement transplanted tumor and minor axis (w).After last administration 48 h, mice is put to death in dislocation, and excision transplanted tumor, takes tumor weight.
Heavy suppression ratio (%) IR=(1-experimental group tumor weight-average value/model control group tumor weight-average value) × 100% of tumor.
The medicine that relatively embodies weighing by tumor suppresses on people's lung cancer A549 cell nude mice the impact that tumor is grown.With mean ± standard deviation, (x ± s) represent adopts SPSS15.0 software to carry out variance analysis to data.
Result of the test shows (referring to table 1): compared with model control group, each treatment group to the inhibitory action of people's lung cancer A549 cell transplanted tumor in nude mice growth all have significant difference (
p< 0.05 or
p< 0.01), this illustrates that heavy dose of clavulanic acid has certain active anticancer.Compared with oxaliplatin group or clavulanic acid group, the average tumour inhibiting rate of drug combination group is significantly increased, the tumour inhibiting rate that especially connection is compared each single medicine group with medication B group have highly significant difference (
p< 0.01), this illustrates that heavy dose of clavulanic acid associating oxaliplatin has the effect of collaborative anti-nonsmall-cell lung cancer.
Each group of impact that people's lung cancer A549 cell transplanted tumor in nude mice is grown of table 1
| Group | Tumor weight/mg | Average tumour inhibiting rate/% |
| Model control group | 369.8±48.1 | |
| Oxaliplatin group | 201.6±53.8 ** | 45.5 |
| Clavulanic acid group | 292.5±31.2 * | 20.9 |
| Connection and medication A group | 152.7±49.0 **$$ | 58.7 |
| Connection and medication B group | 106.3±30.3 **￥￥$$ | 71.3 |
With model control group comparison,
* p< 0.05,
* p< 0.01;
With the comparison of oxaliplatin group,
$ p< 0.05,
$$ p< 0.01;
With the comparison of clavulanic acid group,
$ p< 0.05,
$ $ p< 0.01.
Claims (4)
1. contain an anticancer pharmaceutical composition for clavulanic acid or its salt, it is characterized in that active component is made up of clavulanic acid or its salt and oxaliplatin; The salt of clavulanic acid is by free acid, and the weight ratio of clavulanic acid or its salt and oxaliplatin is 2:1 or 3:1.
2. anticancer pharmaceutical composition according to claim 1, is characterized in that: the salt of clavulanic acid is clavulanate potassium.
3. anticancer pharmaceutical composition according to claim 1, is characterized in that: described pharmaceutical composition is injection, and described injection is injection, freeze-dried powder.
4. the purposes of the active component being formed by clavulanic acid or its salt and oxaliplatin in the medicine of the anti-nonsmall-cell lung cancer of preparation, wherein the salt of clavulanic acid is by free acid, and the weight ratio of clavulanic acid or its salt and oxaliplatin is 2:1 or 3:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310094091.5A CN103127098B (en) | 2013-03-22 | 2013-03-22 | Anti-cancer pharmaceutical composition containing clavulanic acid or salts thereof and pharmaceutical application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310094091.5A CN103127098B (en) | 2013-03-22 | 2013-03-22 | Anti-cancer pharmaceutical composition containing clavulanic acid or salts thereof and pharmaceutical application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103127098A CN103127098A (en) | 2013-06-05 |
| CN103127098B true CN103127098B (en) | 2014-05-14 |
Family
ID=48487972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310094091.5A Active CN103127098B (en) | 2013-03-22 | 2013-03-22 | Anti-cancer pharmaceutical composition containing clavulanic acid or salts thereof and pharmaceutical application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127098B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2546195A1 (en) * | 2003-11-21 | 2005-06-02 | Pfizer Products Inc. | The use of anti biotics as vaccine adjuvants |
-
2013
- 2013-03-22 CN CN201310094091.5A patent/CN103127098B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103127098A (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106822905A (en) | The medicine and purposes of inhibitor containing Survivin and IRE1 inhibitor | |
| US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| US20190183893A1 (en) | Low dose of sildenafil as an antitumor drug | |
| CN103127098B (en) | Anti-cancer pharmaceutical composition containing clavulanic acid or salts thereof and pharmaceutical application | |
| CN112704679A (en) | Pharmaceutical composition containing homoharringtonine and application thereof | |
| CN109793727A (en) | A kind of pharmaceutical composition and its application of effective anti-malignant tumor | |
| CN113663081A (en) | Application of oroxylin and PD-1/PD-L1 inhibitor in preparation of liver cancer treatment drug | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| WO2021023291A1 (en) | Use of proflavine in treatment of lung cancers | |
| CN103202861A (en) | Application of composition of clostridium butyricum and bifidobacterium dual live bacteria preparation and anticancer medicament in preparation of medicament for treating intestinal cancer | |
| CN111939159A (en) | Application of NSC23766 in tumor radiotherapy assisting | |
| CN112220917A (en) | Combined medicine for treating malignant tumor | |
| CN111558045A (en) | Medicine composition for treating lung cancer | |
| CN112076216A (en) | Application of arsenic trioxide in treating gastrointestinal stromal tumor | |
| CN102125558A (en) | Compound sodium levofolinate fluorouracil antineoplastic medicament | |
| CN106668061B (en) | A kind of anticancer pharmaceutical composition containing cis-platinum | |
| CN111494385A (en) | Medicine for treating ovarian cancer and preparation method and application thereof | |
| CN111388665B (en) | Compound for treating tumor and preparation and application thereof | |
| CN110613716A (en) | Pharmaceutical composition for treating cancer and application thereof | |
| CN104147036A (en) | Application of decitabine and oxaliplatin in preparation of combination drug for treating renal cell carcinoma | |
| CN110559287A (en) | Pharmaceutical composition for treating cancer and application thereof | |
| CN108324707A (en) | Fenofibrate list medicine and combined chemotherapy medicine application in preparation of anti-tumor drugs | |
| CN111939165B (en) | Application of non-natural ginsenoside 3 beta-O-Glc-DM in preparation of medicine for preventing or treating glioblastoma | |
| CN102283845B (en) | Application of ectoine and derivatives thereof in preparing tuberculosis treatment medicine | |
| WO2022222388A1 (en) | Use of l-sorbose in preparation of drug for treating tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ying Shuhuan Inventor after: Pi Hongjun Inventor before: Yu Fazhou |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170417 Address after: 202153 Shanghai free trade zone GuoShouJing Road No. 351 Building No. 2 room A679-04 Patentee after: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. Address before: 235000 Anhui Province Economic Development Zone Huaibei City Duji District Tengfei Road No. 7 Patentee before: Yu Fazhou |
|
| TR01 | Transfer of patent right | ||
| CP03 | Change of name, title or address |
Address after: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee after: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Country or region after: China Address before: Room A679-04, Building 2, No. 351 Guoshoujing Road, Shanghai Pilot Free Trade Zone, 202153 Patentee before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20240930 Address after: Room 510, Building 1, No. 111 Hongxing Road, Xiaoshan Economic and Technological Development Zone, Hangzhou City, Zhejiang Province 311217 Patentee after: Zhejiang Medideep Biopharmaceutical Co.,Ltd. Country or region after: China Address before: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee before: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Country or region before: China |